Senate to vote on von Eschenbach nomination today

Share this article:
The US Senate is scheduled to consider Andrew von Eschenbach’s nomination to head the FDA today. The Senate has scheduled a procedural vote that requires the support of 60 senators to advance the nomination to a full vote, Reuters reported. Several senators have praised von Eschenbach’s qualifications to lead the agency and his nomination cleared a Senate committee in September. But three Republican Senators have blocked a full Senate vote. Senate Finance Committee Chairman Charles Grassley of Iowa said he opposed a von Eschenbach confirmation vote because the FDA failed to cooperate with his investigation of Sanofi-Aventis’ antibiotic Ketek and related reports of liver failure. Sen. Jim DeMint of South Carolina opposed a vote due to his concerns about the safety of the abortion pill RU-486. Sen. David Vitter of Louisiana said he will oppose a vote until prescription drug imports are legalized. Spokespeople for each of the three senators told Reuters early today they still object to a vote on von Eschenbach’s nomination.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?